http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110841076-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8882bdeecfb62d78d9221d532b3a8eb7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6931 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
| filingDate | 2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90fa610028663ad9ece0991c56e742c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75da6f7c8fe95071af35f2bbce353e9e |
| publicationDate | 2020-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110841076-A |
| titleOfInvention | Preparation method and application of targeted modified solanine albumin nanoparticle medicine |
| abstract | The invention belongs to the technical field of biological pharmacy, and particularly relates to targeted modified solanine albumin nanoparticles as well as a preparation method and application thereof. The invention adopts PEG and bioactive polypeptide to simultaneously carry out targeted modification on the solanine albumin nanoparticle medicament, and simultaneously adopts a reducing agent to reduce albumin molecules in the preparation process of the solanine albumin nanoparticle, so that the prepared targeted modified solanine albumin nanoparticle medicament has reduction response capability and degradability, can effectively control the solanine medicament to reach a target point and release the medicament, and simultaneously, in vitro experiments and animal model experiments show that the targeted modified solanine albumin nanoparticle can obviously inhibit the proliferation of prostate cancer tumor cells and has good clinical application prospect. |
| priorityDate | 2019-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 92.